Biodexa Pharmaceuticals (BDRX) Competitors $0.84 -0.04 (-4.53%) Closing price 03:59 PM EasternExtended Trading$0.81 -0.03 (-3.81%) As of 07:58 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisChartCompetitorsHeadlinesSEC FilingsShort InterestTrendsBuy This Stock BDRX vs. KRRO, NKTX, IMRX, KYTX, UPXI, PLX, BHST, GNLX, TARA, and ATOSShould you be buying Biodexa Pharmaceuticals stock or one of its competitors? The main competitors of Biodexa Pharmaceuticals include Korro Bio (KRRO), Nkarta (NKTX), Immuneering (IMRX), Kyverna Therapeutics (KYTX), Upexi (UPXI), Protalix BioTherapeutics (PLX), BioHarvest Sciences (BHST), Genelux (GNLX), Protara Therapeutics (TARA), and Atossa Genetics (ATOS). These companies are all part of the "pharmaceutical products" industry. Biodexa Pharmaceuticals vs. Its Competitors Korro Bio Nkarta Immuneering Kyverna Therapeutics Upexi Protalix BioTherapeutics BioHarvest Sciences Genelux Protara Therapeutics Atossa Genetics Korro Bio (NASDAQ:KRRO) and Biodexa Pharmaceuticals (NASDAQ:BDRX) are both small-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their valuation, earnings, dividends, risk, media sentiment, profitability, analyst recommendations and institutional ownership. Do analysts recommend KRRO or BDRX? Korro Bio presently has a consensus price target of $102.43, suggesting a potential upside of 678.33%. Given Korro Bio's stronger consensus rating and higher probable upside, equities research analysts plainly believe Korro Bio is more favorable than Biodexa Pharmaceuticals.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Korro Bio 0 Sell rating(s) 0 Hold rating(s) 5 Buy rating(s) 2 Strong Buy rating(s) 3.29Biodexa Pharmaceuticals 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Which has more volatility and risk, KRRO or BDRX? Korro Bio has a beta of 2.43, suggesting that its stock price is 143% more volatile than the S&P 500. Comparatively, Biodexa Pharmaceuticals has a beta of 1.17, suggesting that its stock price is 17% more volatile than the S&P 500. Does the media favor KRRO or BDRX? In the previous week, Biodexa Pharmaceuticals had 1 more articles in the media than Korro Bio. MarketBeat recorded 3 mentions for Biodexa Pharmaceuticals and 2 mentions for Korro Bio. Korro Bio's average media sentiment score of 0.94 beat Biodexa Pharmaceuticals' score of 0.93 indicating that Korro Bio is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Korro Bio 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Biodexa Pharmaceuticals 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Which has stronger earnings and valuation, KRRO or BDRX? Biodexa Pharmaceuticals has lower revenue, but higher earnings than Korro Bio. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioKorro Bio$4.82M25.63-$83.58M-$9.44-1.39Biodexa Pharmaceuticals$470K65.31-$7.32MN/AN/A Do institutionals & insiders hold more shares of KRRO or BDRX? 13.2% of Korro Bio shares are owned by institutional investors. Comparatively, 17.5% of Biodexa Pharmaceuticals shares are owned by institutional investors. 4.6% of Korro Bio shares are owned by insiders. Comparatively, 0.3% of Biodexa Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth. Is KRRO or BDRX more profitable? Biodexa Pharmaceuticals' return on equity of 0.00% beat Korro Bio's return on equity.Company Net Margins Return on Equity Return on Assets Korro BioN/A -51.64% -37.94% Biodexa Pharmaceuticals N/A N/A N/A SummaryKorro Bio beats Biodexa Pharmaceuticals on 8 of the 14 factors compared between the two stocks. Get Biodexa Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for BDRX and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding BDRX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart BDRX vs. The Competition Export to ExcelMetricBiodexa PharmaceuticalsMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$30.69M$2.92B$5.57B$9.31BDividend YieldN/A2.43%4.23%4.03%P/E RatioN/A20.4928.6119.73Price / Sales65.31265.46412.00173.26Price / CashN/A43.1536.0257.96Price / Book2.907.768.235.67Net Income-$7.32M-$55.11M$3.23B$257.79M7 Day Performance-4.24%0.95%-0.01%0.52%1 Month Performance-19.23%8.44%5.61%8.84%1 Year PerformanceN/A-2.38%26.52%14.18% Biodexa Pharmaceuticals Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)BDRXBiodexa Pharmaceuticals0.2313 of 5 stars$0.84-4.5%N/AN/A$32.15M$470K0.0020Gap DownKRROKorro Bio1.5202 of 5 stars$12.58-5.8%$102.43+714.2%-74.3%$125.36M$2.27M-1.3370NKTXNkarta1.8108 of 5 stars$1.69-3.4%$14.33+748.1%-74.1%$124.18MN/A-1.12140Positive NewsIMRXImmuneering3.2652 of 5 stars$4.05+17.4%$13.25+227.2%+242.6%$124.15MN/A-2.0760Gap DownKYTXKyverna Therapeutics2.6428 of 5 stars$2.55-9.3%$18.50+625.5%-61.5%$121.44M$7.03M-0.7596UPXIUpexi2.2243 of 5 stars$3.26+2.2%$16.00+390.8%-39.5%$121.14M$16.56M0.00130Gap UpHigh Trading VolumePLXProtalix BioTherapeutics2.8048 of 5 stars$1.47-4.5%$15.00+920.4%+19.0%$117.02M$59.76M-11.31200BHSTBioHarvest SciencesN/A$7.06+2.3%$13.67+93.6%N/A$113.33M$27.70M-14.12N/AHigh Trading VolumeGNLXGenelux1.2111 of 5 stars$2.90-2.7%$17.75+512.1%+17.6%$112.45MN/A-3.3010Gap DownTARAProtara Therapeutics2.0692 of 5 stars$2.80-3.1%$20.50+632.1%+28.2%$111.50MN/A-1.6330Positive NewsATOSAtossa Genetics3.1467 of 5 stars$0.85-0.4%$6.17+629.1%-34.7%$109.68MN/A-4.038Positive News Related Companies and Tools Related Companies Korro Bio Competitors Nkarta Competitors Immuneering Competitors Kyverna Therapeutics Competitors Upexi Competitors Protalix BioTherapeutics Competitors BioHarvest Sciences Competitors Genelux Competitors Protara Therapeutics Competitors Atossa Genetics Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:BDRX) was last updated on 7/16/2025 by MarketBeat.com Staff From Our PartnersElon’s Secret Social Security BombshellTo All Americans Born Before April 16th, 1963: Did Trump Just Give The Green Light To Radically RE-DO Social S...Banyan Hill Publishing | SponsoredBuffett’s Little-Known Succession PlanYou could miss out on millions buying a house - even if prices rise Joel Litman is a millionaire member of ...Altimetry | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredPost-Halving = Profit Season (Here’s How to Win It)It happens like clockwork. Every four years, the crypto market enters a new phase — and for those who know how...Crypto Swap Profits | SponsoredThe Trump Dump is starting; Get out of stocks now?The first 365 days of the Trump presidency… Will be the best time to get rich in American history.Paradigm Press | SponsoredSpecial gold investment soars 2,300% ... 5,090% ... 9,850%In my 54 years as an investor, I’ve seen my share of gold bull markets. But nothing comes close to the rall...Weiss Ratings | SponsoredTrump’s treachery Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to ...Porter & Company | SponsoredIs this secretive Asian company trying to take over Bitcoin?A mysterious Asian conglomerate is buying billions in Bitcoin — but one legendary trader says that’s the wrong...Brownstone Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Biodexa Pharmaceuticals PLC Unsponsored ADR Please log in to your account or sign up in order to add this asset to your watchlist. Share Biodexa Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free BDRX Stock Alerts